ChemoCentryx (CCXI), a biopharmaceutical company, reported Monday that its ongoing phase 2 trial of CCX168 for the treatment of atypical hemolytic uremic syndrome demonstrated a mean decrease in thrombus size of 83% after 14 days of dosing.
The ongoing study demonstrated that three patients showed 100% inhibition of thrombus formation and one patient showed greater than 30% inhibition.
“We are especially encouraged to find that with CCX168 treatment a complete inhibition of thrombus formation induced by the serum of three aHUS patients on microvascular endothelium, as well as partial inhibition in the other two patients evaluated to date. This is particularly important, as systemic TMA can lead to heart attack, stroke, and kidney failure, which are the primary causes of mortality associated with aHUS,” said Giuseppe Remuzzi, clinical investigator.
